Prime Medicine, Inc. (NYSE:PRME) Receives $14.11 Consensus Target Price from Analysts
Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has earned an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month […]
4 Oct 05:20 · The Cerbat Gem